Capivasertib Active against AKT1-Mutated Cancers.
The experimental pan-AKT inhibitor capivasertib (AZD5363) helped stabilize or shrink tumor growth in most patients with metastatic AKT1-mutant tumors enrolled in the U.S.-wide NCI-MATCH trial, according to data presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.